Discontinued — last reported Q4 '25
Nasdaq, Inc. Interest Paid increased by 77.5% to $126.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.8%, from $125.00M to $126.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 31.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $51.00M | $9.00M | $39.00M | $23.00M | $37.00M | $23.00M | $33.00M | $37.00M | $30.00M | $22.00M | $88.00M | $145.00M | $81.00M | $89.00M | $90.00M | $125.00M | $84.00M | $74.00M | $71.00M | $126.00M |
| QoQ Change | — | -82.4% | +333.3% | -41.0% | +60.9% | -37.8% | +43.5% | +12.1% | -18.9% | -26.7% | +300.0% | +64.8% | -44.1% | +9.9% | +1.1% | +38.9% | -32.8% | -11.9% | -4.1% | +77.5% |
| YoY Change | — | — | — | — | -27.5% | +155.6% | -15.4% | +60.9% | -18.9% | -4.3% | +166.7% | +291.9% | +170.0% | +304.5% | +2.3% | -13.8% | +3.7% | -16.9% | -21.1% | +0.8% |